BENEBIOSIS CO., LTD.; LTD.;BENEBIOSIS CO.;SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
发明人:
KANG, SEUNG WOO,KIM, CHEORL-HO,KIM, SEOK-JO
申请号：
EP09822176
公开号：
EP2361627A4
申请日:
2009.10.16
申请国别(地区):
EP
年份:
2012
代理人:
摘要：
Provided is a composition for prophylaxis or treatment of an eye disease comprising a compound represented by General Formula I: S - MS p - MS q wherein S represents sialic acid, and (MS) p and (MS) q independently represent a monosaccharide residue. The compound used as the active ingredient inhibits expression of MMP-9 and inflammation-mediated cytokines (IL-1², TNF-±, etc.) in corneal epithelial cells and inhibits VEGF-mediated VEGFR-2 activation in human retinal endothelial cells (HREC), thereby exhibiting prophylactic or therapeutic activity for eye diseases such as dry eye syndrome, inflammatory eye disease, neovascularization-associated eye disease and side effects of wearing of contact lenses. Also, because it has no cytotoxicity or skin side effect, the provided composition may be safely used as a pharmaceutical composition, a neutraceutical composition or a food composition. In addition, the composition may be used as a cleaner or a lubricant for contact lenses since it has nonbacterial antiinflammatory activity and ocular contact lubricating activity.
